Design an Efficient Method for the Synthesis of 2-(1,3-diphenyl-1*H*-pyrazol-4yl)-1H-benzo[d]imidazole

B. Srinivas¹ and Koya Prabhakara Rao^{2*}

Abstract

A simple, highly efficient and environmentally friendly method has been developed for the synthesis of 2-(1,3diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole by using Gadolinium(III) trifluoromethanesulfonate catalyst and ethanol reflux reaction conditions By using this method. 12 new 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1Hbenzo[d]imidazole derivatives were synthesized under optimized reactions conditions. All these new products structures are confirmed by spectral analysis. By this method, we achieved imidazole derivatives with more operational simplicity, short reaction time and good yields (up to 85%).

Keywords: Gadolinium (III), Benzoimidazoles, pyrazoles, One pot reactions, imidazoles

1. Introduction

Benzoimidazoles are important heterocyclic compounds and it's with in their usage as a core construction for multiple and valuable applications¹ in the area of drug discovery and medicinical and argo chemistry such as including antimicrobial² and antifungal,³ cytotoxic,⁴ and antidiabetic⁵ applications and also substituted benzo imidazoles have been designed and synthesized for biological


¹Department of H&S, Guru Nanak Institutions Technical Campus, Hyderabad, Telangana, India; ²New Generation Materials Lab, Department of S & H, VFSTR (Deemed to be University), Vadlamudi, Guntur-522 213, Andhra Pradesh, India; kprao2005@gmail.com

evaluations⁶. Pyrazoles are the privileged compounds for the pharmaceutical and agricultural research,⁷⁻¹² such as Celebrex, Viagra, Zometapine, Cyenopyrafen, Fenpyroximate and Tebufenpyrad and pyrazole containing compounds with in the field of medicinal and agro chemistry like antimicrobial acivities.¹³⁻²²

2. Results and discussion

The reaction optimization conditions was developed for the synthesis of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole derivatives by using Gadolinium (III) trifluoromethanesulfonate catalyst. By the condensation of 1*H*-benzo[d]imidazole and synthesized aldehydes in the simple reaction condition, in the presence of ethanol reflux for 6h offered the final required compound in excellent yield 85%, and then it was purified by the column chromatography.

Initially to optimize the reaction conditions, we administered the reactions at the RT conditions and also as at refluxed conditions under different polar solvents (Table 1, Entries 1-12) like water, methanol and ethanol etc. In our various attempts as mentioned in table 1, we found that under refluxed conditions in ethanol solvent with Gadolinium(III) trifluoromethanesulfonate is as a catalyst, 1 mmol of the reactants provided the good and simplest yield. So as to the effectiveness determine of the Gadolinium(III) trifluoromethanesulfonate catalyst for the synthesis of 2-(1.3diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (3a), test а performed without reaction was Gadolinium(III) trifluoromethanesulfonate catalyst in ethanol solvent using similar reactants under refluxed conditions vielded only 30 % even after 6hrs (Table 1, Entry 7).



Scheme 1. Synthesis of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole using various reaction conditions.

We also administered few model reactions to see viability of the different well known other catalysts like reaction using Ethanoicacid, HCl, Na₂S₂O₅, Gd(OTf)₃, Cu(OTf)₃, and ZnCl₂ etc. Among all our attempts using different catalysts, Gd(OTf)₃ provided the best yield. The simplest optimized conditions were 10 mol % of Gd(OTf)₃ in ethanol solvent under refluxed conditions. During this context, these optimized conditions were employed for the synthesis derivatives of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d] of imidazole (3a-1).

The optimized reaction conditions described above were employed for a series of substituted 1,3-diphenyl-1H-pyrazole-4-carbaldehyde including electron-withdrawing and electron-donating groups. A variety number of substituents in 1,3-diphenyl-1H-pyrazole-4carbaldehyde reacted well during in this protocol and delivered good yields (69-85 %) (Table 2). From the above results we will concluded that, this system can tolerate both electron-withdrawing and electron-donating groups effectively for the synthesis of corresponding derivatives of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1Hbenzo[d]imidazole in good yields. Hence, this system can apply generally for sort of substituents on 1,3-diphenyl-1H-pyrazole-4carbaldehyde to yield derivatives of benzo[d]imidazole derivatives with good vield for reasonable Gadolinium(III) trifluoromethanesulfonate catalyst, less solvent and low reaction time etc. This study provides a road map for the synthesis of new drug molecules by simple direct one pot method (see supporting information for the spectral data).

Table 1. Reaction conditions for 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole

Mapana Journal of Sciences, Vol. 18, No.2

Entry	Solvent	Catalyst	Temperature	Time (h)	Yield ^a		
-		-	(°C)		(%)		
1	-	-	RT	12	-		
2	Methanol	-	RT	12	-		
3	Ethanol	-	RT	12	-		
4	Water	-	RT	12	-		
5	CH ₃ CN	-	RT	12	-		
6	Methanol	-	Reflux	12	25		
7	Ethanol	-	Reflux	12	30		
8	-	Gd(OTf)3	Reflux	6	50		
9	CH ₃ CN	Cu(OTf) ₃	Reflux	6	55		
10	Methanol	Gd(OTf)3	Reflux	6	60		
11	Ethanol	$ZnCl_2$	Reflux	6	45		
12	Methanol	$Na_2S_2O_5$	RT	6	50		
13	Ethanol	HC1	Reflux	6	70		
15	Methanol	Acetic acid	RT	6	50		
15	Ethanol	Gd(OTf) ₃	Reflux	6	85		
$R \rightarrow H \rightarrow $							
	1a-I	2a-l		3a-I			

Scheme 2. Synthetic conditions for derivatives of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole.

Table 2. Reaction conditions for derivatives of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole.

Entry	Product	Yield (%)
1	3a	85

Design an Efficient Method for the Synthesis

	2	3b	77
	3	3c	73
	4	3d	70
	5	3e	79
	6	3f	70
	7	3g	80
	8	3g 3h	72
	9	3i	70
•	10	Зј	69
3.	11	3k	75
	12	31	69

Conclusion

In summary, we've been developed a proto type facile and efficient, mild and easy method for the synthesis of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole, **3(a-l)**, by using Gadolinium(III) trifluoromethanesulfonate as a catalyst in ethanol solvent by this new synthetic method, we achieved 12 new imidazole derivatives with more operational simplicity, low reaction time and good yields (up to 85 %). Moreover, this system can also tolerate both electron-withdrawing and electron-donating groups effectively for the synthesis of corresponding derivatives of **3(a-l)**, in good yields.

Acknowledgement

B Srinivas (B. S) thanks Guru Nanak Institutions for the research avenues. B.S also thanks UGC-SERO, for financial support, Minor Research Project No. 6401/2016/UGC-SERO. Koya Prabhakara Rao (K. P. Rao) thanks DST-SERB, for support, project for early career, project no. **EMR/2014/001114**.

Experimental Section

Materials and methods

Chemical reagents were purchased from Sigma-Aldrich and were used without further purification. Solvents for extraction and column chromatography were distilled prior to use. TLC analysis were performed with silica gel plates (0.25 mm, E. Merck, 60 F254) using ninhydrine, *p*-anisaldehyde, KMnO₄, iodine, and UV lamp for visualization. ¹H and ¹³C NMR experiments were performed on 300 or 500 and 75 or 125 MHz respectively, on a Bruker Avance. Chemical shifts are reported in parts per million (ppm) downstream from the internal tetramethylsilane standard. Spin multiplicities are described as s (singlet), bs (broad singlet), d (doublet), dd (double doublet), t (triplet), q (quartet) and m (multiplet). Coupling constants are reported in Hertz (Hz).

General procedure for the Synthesis of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole: (3a). Equimolar ratio of the three 1H-benzo[d]imidazole reactants, (1 mmol),1,3-diphenyl-1Hpyrazole-4-carbaldehyde were taken in round bottom flask the presence of ethanol dissolved in (10)ml), and add Gadolinium(III) trifluoromethanesulfonate catalyst then the reaction mixture refluxed for 6hrs. The reaction was monitored by TLC. After completion of the reaction the solvent was removed from crude mixture and extracted with ethyl acetate and water. The final compounds were purified by the column chromatography using silica gel by eluted with ethyl acetate and hexane (30:70) to yield 85 %. light White solid, Mp: 172-175 1H NMR (300 MHz, DMSO-d6) d 8.57 (s, 1H), 7.80 & 7.71 (m, 4H), 7.54 (1 Hz, 2H), 7.45 (t, J = 7.8 Hz, 2H), 7.33 & 7.20 (m, 4H), 7.23 (d, 2H). 13C NMR (75 MHz, DMSOd6) d 150.1, 146.3, 137.7, 136.3, 132.8, 129.8, 128.7, 127.1, 126.7, 125.3, 120.5, 117.1, 115.2, 111.3. MS (ESI): m/z 337 [M+H]. HRMS (ESI) calcd for C22H16N4 found: 337.18.

Similar experimental procedure of **3a** was employed for all the remaining derivatives, **3b-31** with yields between 72-85 %.

2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-

benzo[d]imidazole (3b): brown Colour solid, yield 77 %, Mp: 185-187, ¹H NMR (300 MHz, CDCl₃) d 8.53 (s, 1H), 7.70 (d, 2H), 7.69-7.70 (m, 2H), 7.60-7.49 (m, 6H), 7.27 (t, 2H), 7.03-6.93 (m, 1H). ¹³C NMR Srinivas and Rao

(75 MHz, CDCl3) d 160.1, 158.9, 151.7, 147.8, 138.3, 131.3,128.4,128.9,127.1,126.8,125.6,124.4,118.1,116.5,115.0,111.7.; MS (ESI): m/z 354.38 [M+H]. HRMS (ESI) calcd for $C_{22}H_{15}N_4F$ found: 354.19.

2-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazole

(3c): light yellow solid, yield 73 %, Mp: 170-173, ¹H NMR (300 MHz, CDCl₃) 8.70 (s, 1H), 7.67 (d, J= 7.5 Hz, 2H), 7.59 (d, J = 3.1 Hz, 2H), 7.53-7.49 (m, 6H), 7.44 (d, J=7.3 Hz, 2H), 7.6 (d, 1H), 2.35 (s, 3H). ¹³C NMR (125 MHz, CDCl3) 150.7, 146.8, 138.2, 133.8, 130.3, 131.6, 130.0, 129.8, 128.2, 127.4, 127.1, 126.5, 125.1, 120.3, 119.8, 117.8, 113.6, 23.6.; MS (ESI): m/z 351 [M+H]. HRMS (ESI) calcd for $C_{23}H_{18}N_4$ [found: 351.11.

2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-

benzo[d]imidazole (3d): yellow solid, yield 70 %, Mp: 189-190, 1H NMR (400 MHz, CDCl₃) d 8.57 (s, 1H), 7.80-7.75 (m, 2H), 7.70 (d, J = 5.8, Hz, 2H), 7.63-7.54 (m, 6H), 7.44 (t, J= 7.5 Hz, 2H), 6.88 (d, J= 2.4 Hz, 1H), 3.73 (s, 3H). ¹³C NMR (125 MHz, CDCl3) 157.5, 151.3, 146.6, 138.1, 133.2, 130.6, 129.8, 128.0, 127.7, 126.9, 125.4, 125.9, 119.6, 119.3, 117.8, 115.9, 111.2, 56.8.; MS (ESI): m/z 366 [M+H]b. HRMS (ESI) calcd for C_{23} H₁₈ON₄ found: 366.50.

6-chloro-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1Hbenzo[d]imidazole (3e): Yellow solid, yield 79%, Mp: 188-190, ¹H NMR (300 MHz, CDCl3) 8.37 (s, 1H), 7.72 (d,

J = 7.64 Hz, 2H), 7.50-7.39 (m, 4H), 7.26-7.14 (m, 3H), 7.18 (d, J = 7.6 Hz, 1H), 6.56 (d, J = 8.5 Hz, 2H), 3.68 (s, 3H). ¹³C NMR (75 MHz, CDCl3) 161.1, 157.7, 146.0, 138.2, 131.5, 127.4, 127.1, 126.7, 126.01, 124.3, 123.1, 118.4, 114.4, 112.5, 56.2.; MS (ESI): m/z 401 [M+H]. HRMS (ESI) calcd for $C_{23}H_{17}ON_4Cl$, found: 400.14.

6-fluoro-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1Hbenzo[d]imidazole (3f): brown solid, yield 70 %, Mp: 171-174, ¹H NMR (500 MHz, CDCl₃) 8.74 (s, 1H), 7.83 (d, J= 7.9 Hz, 2H), 7.73 (d, J= 8.44 Hz, 2H), 7.57-7.43 (m, 4H), 7.39 (t, J = 7.4 Hz, 1H), 7.02-6.85 (m, 3H), 3.90 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) 161.2, 160.9, 159.3, 151.7, 148.2, 140.3, 139.6, 129.7, 128.1, 121.8, 120.6, 119.8, 117.9, 113.3, 118.6, 110.2, 54.1.; MS (ESI): m/z 384 [M+H] ; HRMS (ESI) calcd for C₂₃H₁₇ON₄F found: 384.56.

2-(1,3-diphenyl-1H-pyrazol-4-yl)-6-fluoro-1H-benzo[d]imidazole (**3g**): brown Colour solid, yield 80 %, Mp: 187-190, ¹H NMR (300 MHz, CDCl₃) d 8.54 (s, 1H), 7.60 (d, 2H), 7.59-7.70 (m, 2H), 7.50-7.49 (m, 6H), 7.27 (t, 2H), 7.03-6.63 (m, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 161.1, 159.9, 152.7, 148.8, 139.3, 132.3,129.4,128.9,128.1,126.8,125. 6, 124.4,119.1,118.5,116.0,112.7.; MS (ESI): m/z 354 [M+H]. HRMS (ESI) calcd for C₂₂H₁₅N₄F found: 354.43.

2-(1,3-diphenyl-1H-pyrazol-4-yl)-6-chloro-1H-benzo[d]imidazole (**3h**): Light White solid, yield 72%, Mp: 191-193, ¹H NMR (300 MHz,

CDCl3) 8.77 (s, 1H), 7.67 (d, J =7.5 Hz, 2H), 7.78 (d, J = 6.5, 3.0 Hz, 2H), 7.55-7.42 (m, 6H), 7.45 (t, J =7.4 Hz, 2H), 7.20 (d, J =7.4 Hz, 1H). ¹³C NMR (75 MHz, DMSO-d₆), 151.1, 148.4, 139.2, 132.4, 129.8, 127.7, 127.1, 126.6, 126.31, 123.6, 116.1, 112.8, 110.4.; MS (ESI): m/z 371 [M +H]. HRMS (ESI) calcd for $C_{22}H_{15}N_4Cl$, 370.10; found: 370.04.

6-chloro-2-(1-phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)-1H-

benzo[d]imidazole (3i): yellow solid, yield 70 %, Mp: 173-176, ¹H NMR (300 MHz, CDCl3), 8.58 (s, 1H), 7.73 (d, J= 7.6 Hz, 2H), 7.53 (d, J= 8.4 Hz, 2H), 7.40-7.32 (m, 7H), 7.18 (d, J = 8.22 Hz, 1H), 2.56 (s, 3H). ¹³C NMR (75 MHz, CDCl3), 149.1, 146.1, 139.0, 133.6, 131.4, 130.0, 128.6, 128.1, 127.0, 125.7, 122.3, 116.5, 1112.9, 20.4.; MS (ESI): m/z 385 [M+H]. HRMS (ESI) calcd for C₂₃H₁₇ClN₄ found: 385.23.

5,6-dichloro-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (3j): Light red solid, yield 69 %, Mp: 206-209, ¹H NMR (500 MHz, CDCl₃) 8.63 (s, 1H), 7.85 (d, J =7.7 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 7.63 (s, 2H), 7.19 (d, J = 5.1 Hz, 2H), 7.23 (t, J = 7.4 Hz, 1H), 6.95-6.76 (m, 2H), 3.71 (s, 3H). ¹³C NMR (75 MHz, CDCl3) 152.3, 151.3, 149.0, 137.8, 128.2, 129.1, 126.5, 123.7, 122.2, 118.2, 113.1, 111.8, 54.7.; MS (ESI): m/z 435 [M+H]. HRMS (ESI) calcd for C₂₃H₁₆ON₄Cl₂ found: 435.07502.

6-chloro-2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1Hbenzo[d]imidazole (3k): White solid, yield 75 %, Mp: 191-195, ¹H NMR (300 MHz, CDCl₃) 8.72 (s, 1H), 7.55 (d, J = 7.7 Hz, 2H), 7.69-7.52 (m, 2H), 7.44-7.45 (m, 3H), 7.38-7.31 (m, 2H), 7.13e7.09 (m, 2H), 6.10 (t, J= 8.5 Hz, 1H); 13C NMR (75 MHz, CDCl₃) 161.5, 160.3, 148.1, 145.4, 138.0, 137.8, 135.0, 129.4, 128.2, 127.8, 126.7, 122.3, 118.0, 114.5, 113.2, 109.1; MS (ESI): m/z 389 [M+H]. HRMS (ESI) calcd for C₂₂H₁₄ClFN₄ found: 389. 07.

2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-methyl-1H-

benzo[d]imidazole (31): brown solid, yield 69 %, Mp: 183-185, 1H NMR (500 MHz, CDCl3) 8.45 (s, 1H), 7.68-7.59 (m, 4H), 7.40 (d, J =7.3 Hz, 1H), 7.34 (t, J = 7.4 Hz, 2H), 7.38-7.32 (m, 2H), 7.06 (d, J = 8.2,Hz, 1H), 6.88 (t, J = 8.49 Hz, 2H), 2.46 (s, 3H). ¹³C NMR (75 MHz, CDCl3) 165.1, 164.1, 148.8, 146.23, 139.3, 132.8, 130.1, 130.3, 128.5, 127.8, 127.4, 127.1, 124.4, 119.0, 115.4, 115.1, 112.8, 21.9.; MS (ESI): m/ z 368 [M+H]. HRMS (ESI) calcd for C₂₃H₁₇FN₄ found: 368.15

References

- Abdel-Wahab, B. F.; Abdel-Aziz, H. A.; Ahmed, E. M. Eur. J. Med.m Chem. 2009, 44, 2632.
- [2] Kaniwa, K.; Ohtsuki, T.; Yamamoto, Y.; Ishibashi, M. Tetrahedron Lett. 2006, 47, 1505.
- [3] Di Nunno, L.; Franchini, C.; Scilimati, A.; Sinicropi, M. S.; Tortorella, P. Tetrahedron: Asymmetry 2000, 11, 1571. Moreno-Díaz, H.; Villalobos-Molina, R.; Ortiz-Andrade, R.; Díaz-Coutiño, D.; Medina-Franco, J. L.; Webster, S. P.; Binnie, M.; Estrada-Soto, S.; Ibarra-Barajas, M.; Leon-Rivera, I.; Navarrete- Vazquez, G. Bioorg. Med. Chem. Lett. 2008, 18, 2871.
- [4] Srinivas, B., Devi, N. S., Sreenivasulu, G. K., & Parameshwar, R. Synthesis And Characterization Of Pyrrolo [2, 1-C][1, 4] Benzodiazepine-Circumdatin Conjugates. *Heterocyclic Letters*, 2015, 5(3), 459-466.
- [5] Srinivas, B., Devi, N. S., Sreenivasulu, G. K., & Parameshwar, R. Synthesis and characterization of quinazolino-benzodiazepinebenzothiazole-hybrid derivatives." *Der Pharma Chemica*, 2015, 7(5), 251-256.
- [6] Scheetz, M. E.; Carlson, D. G.; Schinitsky, M. R. Infect. Immun. 1977, 15, 145. (c) Ricote, M.; Valledor, A. F.; Glass, C. K. Arterioscler., Thromb., Vasc. Biol. 2004, 24, 230.
- [7] (d) Khurmi, N. S.; Bowles, M. J.; O'Hara, M. J.; Lahiri, A.; Raftery, E. B. Int. J. Cardiol. 1985, 9, 289.
- [8] A.A.O. Sarhan, A. Al-Dhfyan, M.A. Al-Mozaini, C.N. Adra, T.A. Fadl, Cell cycle disruption and apoptotic activity of 3aminothiazolo[3,2-a]benzimidazole-2carbonitrile and its homologues, Eur. J. Med. Chem. 45 (2010) 2689-2694.
- [9] A.A. El Rashedy, H.Y. Aboul-Enein, Benzimidazole derivatives as potential anticancer agents, Mini Rev. Med. Chem. 13 (2013) 399-407.

- [10] Q. Guan, C. Han, D. Zuo, M. Zhai, Z. Li, Q. Zhang, Y. Zhai, X. Jiang, K. Bao, Y. Wu, W. Zhang, Synthesis and evaluation of benzimidazole carbamates bearing indole moieties for antiproliferative and antitubulin activities, Eur. J. Med. Chem. 87 (2014) 306-315.
- [11] Husain, M. Rashid, M. Shaharyar, A.A. Siddiqui, R. Mishra, Benzimidazole clubbed with triazolo-thiadiazoles and triazolothiadiazines: new anticancer agents, Eur. J. Med. Chem. 62 (2013) 785-798.
- [12] K. Paul, S. Bindal, V. Luxami, Synthesis of new conjugated coumarinbenzimidazole hybrids and their anticancer activity, Bioorg. Med. Chem. 15 (2013) 3667e3672.
- [13] Akita, Y.; Inoue, A.; Yamamoto, K.; O Shimizu, M. Heterocycles 1985, 23, 2327.
- [14] Ohkuwa, T.; Chiba, M.; Fukunaga, R.; Miyafuji, N.; Aoyagi, Y. Heterocycles 1990, 31, 1951.
- [15] Srinivas Boddupally, Prashanth Jyothi, Mandava Venkata Basaveswara Rao, Koya Prabhakara Rao. Design and Synthesis of Antimicrobial Active, (E)-(3-(substituted-styryl)-7H-furo[2,3f]chromen-2-yl)(phenyl)methanone Derivatives and their in Silico Molecular Docking studies. J. Heterocyclic Chem. 2019; 56(1); 73-80.
- [16] Srinivas B, Jettiboina Suryachandram, Katyayani Devi Y, Koya Prabhakara Rao. Synthesis and Antibacterial activity Studies of 8, 9 Di Hydro [7h] Benzo 1,2,4-Oxadiazoles And Its Coumarin Derivatives. J. Heterocyclic Chem. 2017; 54(6); 3730-3734.
- [17] Srinivas B, Jettiboina Suryachandram, Sadanandam P, Rao MVB, Koya Prabhakara Rao. A Facile Synthetic Method for the Synthesis of new 7',9' dihydrospiro[indoline-2,11'-pyrazolo[3,4f]pyrimido[4,5-b]quinoline]-3,8',10' (1'H,6'H)-trione and its Biological Evaluation. Journal of Pharmaceutical Sciences and Research, 2019; 11(5); 1918-1925.
- [18] Devi NS, Srinivas B and Sarangapani M: Synthesis and screening N-(2, 4'-dioxo-1, 2-dihydro-3'H-spiro[indole-3,2'-[1,3]thiazolidin]-3'yl)-2-hydroxybenzamides for anti-bacterial activity. Int J Pharm Sci & Res2019; 10(8): 3850-55
- [19] Devi, N. S., Srinivas, B., & Sarangapani, M. Synthesis and Screening of 3-(4-Oxo-2-Phenyl-1, 3-Thiazol-5 (4h)-Ylidene)-1, 3-Dihydro-2h-Indol-2-One-N-Methylanilines for Antiinflammatory Activity. Journal of Pharmaceutical Sciences and Research, 2019, 11(3), 741-746.
- [20] Parameshwar R, Harinadha Babu. V, Manichandrika. P, Narendra Sharath Chandra JN, Venkata Ramana Reddy M, Srinivas.B

"Pyrazole scaffold: a promising tool in the development of antiproliferative agents." *Journal of Global Trends in Pharmaceutical Sciences*, 2019, 6(3), 2728-2744.

 [21] (a) L.; Derridj, F.; Djebbar, S.; Doucet, H. Tetra 2926. (b) Derridj, F.; Roger, J.; Djebbar, S.; D 2010, 12, 4320. (c) Chen, L.; Roger, J.; Brunea Doucet, H. Chem. Commun. 2011, 47, 1872.